Impact of COVID-19 on Gene Therapy Market: Key Growth Factors and Opportunity Analysis by 2026

According to a new report titled "The Gene Therapy Market by Vector Type, Gene Type and Application: Global Opportunity Analysis and Industry Forecast from 2019 to 2026," published by Allied Market Research, the gene therapy market size is $393.35 million in 2018. . It is estimated to reach $6,205.85 million by 2026, an annual average increase of 34.8% from 2019 to 2026.

Gene therapy is a promising therapy applicable to a wide range of diseases; Their goal is to fundamentally treat the cause of the disease, rather than just alleviating symptoms. It can be effective against a wide range of previously untreated diseases, such as blood, eye, neurodegenerative diseases, and multiple cancers. For example, an adeno-related AAV2 vector carrying an intraretinal injection of the therapeutic gene (RPE65) improved vision in patients with Lever congenital aneurysms. Gene therapy can be administered in combination with cellular products and directly through an in vitro treatment mode (eg Stream Bellis) or in vitro (eg Glybera). Several vectors, including adenovirus (AV), adeno-associated virus (AAV), and lentivirus, present clinically relevant options.

Click here to access the free sample report: https://www.alliedmarketresearch.com/request-sample/2841

Increased funding for gene therapy-related R&D activities and increased awareness of gene therapy are key factors driving the growth of the gene therapy market. In addition, increased government support, ethical acceptance of gene therapy for cancer treatment, and increased cancer incidence can accelerate the growth of the gene therapy market. However, the high costs associated with treatment and unwanted immune responses are expected to hinder the growth of the gene therapy market.

Among the vector types, non-viral vectors are expected to be advantageous in the global gene therapy market due to technological advances such as physicochemical approaches including substances such as lipids, naked DNA, chromosomes, plasmids, cationic polymers and conjugates. Complexes of these vectors with positive results for these treatments during preclinical and clinical trials for the treatment of the disease.

Of the gene types, antigens account for two-thirds of the global gene therapy market share in 2018 and account for the overall market share. Among the areas of application, the oncology disorders sector is the largest contributor to the growth of the gene therapy market due to the growth of the gene therapy market Availability of many gene therapy products that can be used to treat cancer and large patient populations. In addition, there are many gene therapies that are undergoing clinical trials for cancer and cardiovascular disease.

In 2018, North America made the largest contribution to total sales and is expected to continue this trend in gene therapy market during the forecast period. This is due to the high incidence of cancer, high disposable income, and high funding for R&D activities related to gene therapy. However, in the Asia-Pacific region, CAGR is expected to be highest during the forecast period due to increased cancer incidence, increased government initiatives to improve healthcare infrastructure, and increased healthcare spending.

Purchase Inquiries: https://www.alliedmarketresearch.com/purchase-enquiry/2841

Key results of the gene therapy market:
• Non-viral vector segments are expected to grow at the highest rate with a CAGR of 34.6% during the analysis period.
• It has the highest revenue in oncology disorders and is expected to continue to dominate the global gene therapy market in the future.
• The Asia Pacific region is expected to grow at fasting CAGR during the forecast period.
• China is expected to grow the most in the Asia Pacific region during the forecast period.
• Tumor suppressors are expected to grow fastest during the forecast period.

This report provides a comprehensive analysis of key players operating in the global gene therapy market industry: Adaptimmune Therapeutics Plc., Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Gives. Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc., Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure NV, Voyager Therapeutics, Inc.

Other major players in the value chain (company not included in the report) include Amgen, Epeius Biotechnologies, Sanofi, Juno Therapeutics and Advantagene.

Get detailed (COVID-19 impact) analysis:https://www.alliedmarketresearch.com/gene-therapy-market

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.